SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Whipsaw who wrote (3040)12/4/1997 3:13:00 PM
From: Brian Pastor  Read Replies (2) | Respond to of 23519
 
Guess what. We can't read it becuase you have to be a registered member. Could you super copy it to the thread?



To: Whipsaw who wrote (3040)12/5/1997 11:24:00 AM
From: mc  Read Replies (1) | Respond to of 23519
 
Interesting to note from the 10-K is that the agreement does not preclude Janssen from distributing oral meds for ED if they are deemed to be complimentary. The fact that they will not allow any distribution of a locally applied treatment whether complimentary or not raises the question that maybe Vivus is anticipating, even more so than most of us, that some of the orals being proposed will work well in combination with MUSE.

Gary


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News